In the Early Breast Cancer Trialists’' Collaborative group (EBCTCG) meta-analysis17, with a median follow-up of 10.7 years, 26.60% of patients had recurrence of HER2 breast cancer and 19.70% died. This evidence concerns the gene ERBB2 and breast carcinoma.